Pfizer

News

Pfizer, Valneva shrug off phase 3 Lyme disease vaccine miss

Missing the primary endpoint in a phase 3 trial will not stop Pfizer from submitting Valneva-partnered Lyme disease vaccine for approval.

News

GSK's RSV shot cleared in US for all adults

GSK is back on level pegging with its rivals in the RSV vaccine category in the US, after getting FDA approval for Arexvy in the 18 to 49 age bracket.

News

China's clears Pfizer GLP-1 ecnoglutide for weight loss

Pfizer has claimed its first regulatory approval for a GLP-1 agonist in obesity, getting a green light in China for Sciwind-sourced ecnoglutide.

News

UK body raps Sanofi for disparaging Pfizer's RSV jab

Sanofi been found to be in breach of the UK pharma industry's code of practice over an article in which it compared its RSV jab to a Pfizer rival.

News

CMS's Medicare price negotiations start round three

The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.

News

Change of heart as NICE backs prostate cancer drug Talzenna

Thousands of men with prostate cancer will be offered a new treatment, Pfizer's Talzenna, after NICE made an about-turn on the drug.

Pfizer, Valneva shrug off phase 3 Lyme disease vaccine miss

GSK's RSV shot cleared in US for all adults

China's clears Pfizer GLP-1 ecnoglutide for weight loss

UK body raps Sanofi for disparaging Pfizer's RSV jab

CMS's Medicare price negotiations start round three

Change of heart as NICE backs prostate cancer drug Talzenna

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

Pfizer

Editor's Picks